These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity. Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563 [TBL] [Abstract][Full Text] [Related]
33. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report. Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180 [TBL] [Abstract][Full Text] [Related]
34. Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX. Yoo KY; Jung SY; Hwang SH; Lee SM; Park JH; Nam HJ Blood Res; 2018 Mar; 53(1):41-48. PubMed ID: 29662861 [TBL] [Abstract][Full Text] [Related]
35. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. He S; Blombäck M; Jacobsson Ekman G; Hedner U J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322 [TBL] [Abstract][Full Text] [Related]
36. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333 [TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study. Atsou S; Furlan F; Duchemin J; Ellouze S; Sourdeau É; Launois A; Roussel-Robert V; Stieltjes N; Combe S; Fontenay M; Curis E; Jourdi G Eur J Pharmacol; 2021 Jan; 891():173764. PubMed ID: 33249076 [TBL] [Abstract][Full Text] [Related]
38. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays. Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742 [TBL] [Abstract][Full Text] [Related]
39. A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity. Matsumoto T; Nogami K; Shima M Int J Hematol; 2017 Feb; 105(2):174-183. PubMed ID: 27730530 [TBL] [Abstract][Full Text] [Related]
40. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B. Marlar RA; Strandberg K; Shima M; Adcock DM Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]